Pliant Therapeutics, Inc. discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins.
